NCT07644013 Prospective Multicenter Registry Study of Multiple System Atrophy in China
| NCT ID | NCT07644013 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Multiple System Atrophy |
| Study Type | OBSERVATIONAL |
| Enrollment | 214 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 214 participants in total. It began in 2025-06-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited. This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.
Eligibility Criteria
Inclusion Criteria 1. Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or 2. Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or 3. Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate. 4. Age between 40 and 75 years. 5. Ability to provide informed consent or availability of a legally authorized representative when applicable. Exclusion Criteria 1. Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation. 2. Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome. 3. Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes. 4. Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis. 5. Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes. 6. Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.
Contact & Investigator
Yunchuang Sun, MD
✉ sychuang0805@163.comZhaoxia Wang, MD
PRINCIPAL INVESTIGATOR
Department of Neurology, Peking University First Hospital
Frequently Asked Questions
Who can join the NCT07644013 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Multiple System Atrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07644013 currently recruiting?
Yes, NCT07644013 is actively recruiting participants. Contact the research team at sychuang0805@163.com for enrollment information.
Where is the NCT07644013 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07644013 clinical trial?
NCT07644013 is sponsored by Peking University First Hospital. The principal investigator is Zhaoxia Wang, MD at Department of Neurology, Peking University First Hospital. The trial plans to enroll 214 participants.